Results 61 to 70 of about 4,295 (215)

Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron

Therapeutics and Clinical Risk Management, 2015
Michelle Zhou, Marko Popovic, Mark Pasetka, Natalie Pulenzas, Soha Ahrari, Edward Chow, Carlo DeAngelis Department of Pharmacy, Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada Purpose: Nausea and
Zhou M, Popovic M, Pasetka M, Pulenzas N, Ahrari S, Chow E, DeAngelis C   +6 more
doaj  

An Integrated In Silico and In Vivo Approach to Identify Protective Effects of Palonosetron in Cisplatin-Induced Nephrotoxicity

Pharmaceuticals, 2020
Cisplatin is widely used to treat various types of cancers, but it is often limited by nephrotoxicity. Here, we employed an integrated in silico and in vivo approach to identify potential treatments for cisplatin-induced nephrotoxicity (CIN).
Eri Wakai, Yuya Suzumura, Kenji Ikemura, Toshiro Mizuno, Masatoshi Watanabe, Kazuhiko Takeuchi, Yuhei Nishimura   +6 more
doaj   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Ion channels

British Journal of Pharmacology, Volume 182, Issue S1, Page S152-S241, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Jörg Striessnig, Alasdair J. Gibb, Alistair A. Mathie, Emma L. Veale, Eamonn Kelly, Chloe J. Peach, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Richard W. Aldrich, Bernard Attali, Austin M. Baggetta, Elvir Becirovic, David J. Beech, Martin Biel, Roslyn M. Bill, Ana I. Caceres, William A. Catterall, Han Chow Chua, Alex C. Conner, Henry Danahay, Paul Davies, Katrien De Clerq, Markus Delling, Francesco Di Virgilio, Simonetta Falzoni, Wei Fang, Stefanie Fenske, Anna Fortuny‐Gomez, Samuel Fountain, George K. Chandy, Mohammad‐Reza Ghovanloo, Steve A. N. Goldstein, Martin Gosling, Christian Grimm, Stephan Grissmer, Kotdaji Ha, Tim G. Hales, Verena Hammelmann, Israel Hanukoglu, Meiqin Hu, Ad P. Ijzerman, Sairam V. Jabba, Mike Jarvis, Anders A. Jensen, Sven E. Jordt, Leonard K. Kaczmarek, Stephan Kellenberger, Charles Kennedy, Brian King, Philip Kitchen, Qiang Liu, Joseph W. Lynch, Rian W. Manville, Jessica Meades, Verena Mehlfeld, Annette Nicke, Stefan Offermanns, Edward Pérez‐Reyes, Leigh D. Plant, Stephan A. Pless, Lachlan D. Rash, Dejian Ren, Hussein N. Rubaiy, Mootaz M. Salman, Werner Sieghart, Lucia G. Sivilotti, Trevor G. Smart, Terrance P. Snutch, Paolo Tammaro, Jinbin Tian, James S. Trimmer, Charlotte Van den Eynde, Paola Vergani, Joris Vriens, Stephen G. Waxman, Aguan D. Wei, Brenda T. Winn, Heike Wulff, Haoxing Xu, Fan Yang, Lixia Yue, Xiaoli Zhang, Michael Zhu   +86 more
wiley   +1 more source

A prospective, randomized, double-blind trial to compare body weight-adjusted and fixed doses of palonosetron for preventing postoperative nausea and vomiting in obese female patients.

PLoS ONE, 2020
BackgroundPostoperative nausea and vomiting (PONV) is a common postsurgical complication. Palonosetron is effective for PONV prevention at the usual dose of 75 μg, but the ideal dose for obese patients has not yet been investigated. The aim of this study
Nathalia Gouveia de Araujo Ferreira, Ismar Lima Cavalcanti, Alexandra Rezende Assad, Louis Barrucand, Estêvão Luiz Carvalho Braga, Nubia Verçosa   +5 more
doaj   +1 more source

Seizure associated with palonosetron

Supportive Care in Cancer, 2009
In 2003, FDA approved palonosetron as an effective drug for the control ofnausea and vomitingassociated tochemotherapy. Palonosetron is suggested in case of emetogenic chemotherapy schedules, in particular, in the case of cisplatin, high-dose cyclophosphamide, and anthracyclines.
Zambelli A, Sagrada P, Pavesi L
openaire   +3 more sources

5-HT3 Receptor Brain-Type B-Subunits are Differentially Expressed in Heterologous Systems. [PDF]

, 2015
Genes for five different 5-HT3 receptor subunits have been identified. Most of the subunits have multiple isoforms, but two isoforms of the B subunits, brain-type 1 (Br1) and brain-type 2 (Br2) are of particular interest as they appear to be abundantly ...
Bouzat, Cecilia, Corradi, Jeremias, Lummis, Sarah CR, McGonigle, Ian, Price, Kerry L, Thompson, Andrew J   +5 more
core   +3 more sources

Feasibility of an Intravenous Home Chemotherapy Intervention With Low‐Dose Cytarabine Administered by Parents (INTACTatHome)

Pediatric Blood &Cancer, Volume 72, Issue 11, November 2025.
ABSTRACT Background: Intravenous home chemotherapy (IHC) can reduce the frequency of hospital visits and positively affect the child's and the family's everyday life. Knowledge about IHC is needed to enhance evidence‐based provision and implementation. This study aimed to evaluate the feasibility of an IHC intervention.
Louise Ingerslev Roug, Lisa Lyngsie Hjalgrim, Tenna Ruest Haarmark Nielsen, Martha Krogh Topperzer, Mary Jarden, Anders Tolver, Astrid Eliasen, Ayo Wahlberg, Rikke Thenning Michelsen, Helena Hansson   +9 more
wiley   +1 more source

Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens

BMC Pharmacology and Toxicology, 2019
Background Nausea is more difficult to control than vomiting in chemotherapy. We therefore analyzed the efficacy of a strong supportive treatment with aprepitant, palonosetron, and dexamethasone against nausea for various moderately emetogenic ...
Naohisa Yoshida, Tetsuya Taguchi, Masayoshi Nakanishi, Ken Inoue, Tetsuya Okayama, Takeshi Ishikawa, Eigo Otsuji, Koichi Takayama, Haruo Kuroboshi, Motohiro Kanazawa, Yoshito Itoh   +10 more
doaj   +1 more source

The final transformation of Étaín [PDF]

, 2016
Background Although serotonin (5-HT3) receptor antagonists are effective in reducing nausea and vomiting, they may be associated with increased cardiac risk.
Antony, Jesmin, Ashoor, Huda, Blondal, Erik, Cardoso, Roberta, Hemmelgarn, Brenda R, Ho, Joanne, Ivory, John, Johnson, Christy, Lillie, Erin, Ng, Carmen, Nincic, Vera, Reynen, Emily, Roberts, Derek J, Soobiah, Charlene, Straus, Sharon E, Strifler, Lisa, Tricco, Andrea C, Vafaei, Afshin, Veroniki, Areti A   +18 more
core   +3 more sources

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy

Cancer Management and Research, 2009
Rudolph M NavariIndiana University School of Medicine South Bend, South Bend, IN USAAbstract: Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life.
Rudolph M Navari
doaj